Anthony King. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Amino Acid SubstitutionAngiopoietin-like Proteins/deficiencyAngiopoietin-like Proteins/geneticsAnimalsAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedApolipoprotein B-100/deficiencyApolipoprotein B-100/geneticsApolipoproteins C/geneticsCRISPR-Cas Systems/geneticsCholesterol, LDL/bloodDisease Models, AnimalDystrophin/geneticsDystrophin/metabolismGene Editing/methodsGene Editing/trendsGenetic Therapy/methodsGenetic Therapy/trendsHeart Diseases/bloodHeart Diseases/geneticsHeart Diseases/prevention & controlHeart Diseases/therapyHumansHypercholesterolemia/bloodHypercholesterolemia/geneticsHypercholesterolemia/prevention & controlLipoprotein(a)/deficiencyLipoprotein(a)/geneticsMiceMuscular Dystrophy, Duchenne/geneticsMuscular Dystrophy, Duchenne/therapyMutationMyocardial Ischemia/drug therapyMyocardial Ischemia/geneticsMyocardial Ischemia/prevention & controlPatient SafetyProprotein Convertase 9/antagonists & inhibitorsProprotein Convertase 9/geneticsProprotein Convertase 9/metabolismStroke/drug therapyStroke/geneticsStroke/prevention & control
Substances： See more » ANGPTL3 protein, humanAPOB protein, humanAPOC4 protein, humanAngiopoietin-like ProteinsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedApolipoprotein B-100Apolipoproteins CCholesterol, LDLDystrophinLipoprotein(a)PCSK9 protein, humanProprotein Convertase 9evolocumab
Year: 2018 PMID： 29517035 DOI： 10.1038/d41586-018-02482-4
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962